Secretory phospholipase A2‐IIa is a target gene of the HER/HER2‐elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer

Abstract

We found that Heregulin-α, in addition to EGF, contributes to sPLA2-IIa overexpression in prostate cancer cells. Our findings support the notion that high levels of plasma sPLA2-IIa may serve as a poor prognostic biomarker capable of distinguishing aggressive from indolent prostate cancers, which may improve decision-making and optimize patient management.